![Photo](/media/story/7369/thumbnail.jpg)
Advanced melanoma
An increase in survival in metastatic melanoma – the cancer with the most rapidly increasing incidence across the EU – has been shown for the first time in a major international study by researchers from across Europe. The results showed that patients who received a novel monoclonal antibody called ipilimumab lived 34% longer than control patients given gp100 peptide vaccine.